November 03, 2026

To,
The General Manager
Department of Corporate Services
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai - 400 001

COMPANY CODE : BAYERCROP
SCRIP CODE : 506285

Dear Sir / Madam,

Sub.: Unaudited Financial Results along with Limited Review Report of the Company for the quarter and the half year ended September 30, 2026, and Outcome of Board Meeting – November 03, 2026.

Pursuant to Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Board of Directors at their meeting held today i.e., November 03, 2026, has inter alia,

1. Approved the Unaudited Financial Results of the Company for the quarter and half year ended on September 30, 2026. We attach herewith a copy of the Unaudited Financial Results along with the Limited Review Report thereon from the Statutory Auditors, Deloitte Haskins & Sells LLP (ICAI Firm Registration No. 117366W/W-100018).

2. Declared an Interim Dividend of Rs. 90/- per Equity Share of Rs. 10/- each for the Financial Year 2026-27. The said Interim Dividend will be paid on Monday, November 30, 2026, to those shareholders whose names appear in the Register of Members of the Company as on the Record Date i.e., Thursday, November 12, 2026.

Further, please take note that the Board Meeting commenced at 04:00 p.m. (IST) and concluded at 05:15 p.m. (IST).

We request you to take the same on record.

Thanking You.

Yours faithfully,
for **Bayer CropScience Limited**

Bharati Ratan Shetty
Digitally signed by Bharati Ratan Shetty
Date: 2026.11.03 18:18:21 +05'30'

Bharati Shetty
Company Secretary and Compliance Officer
(Membership No.: ACS 24199)

Bayer CropScience Ltd.
CIN: L24210MH1958PLC011173

Registered and Corporate Office:
Bayer House
Central Avenue
Hiranandani Estate
Thane (West) – 400 607
Maharashtra, India

Tel : +91 22 2531 1234
Fax : +91 22 2545 5063
www.bayer.in
www.cropscience.bayer.com

RESTRICTED

Deloitte
Haskins & Sells LLP

Chartered Accountants
One International Center,
Tower 3, 31st Floor,
Senapati Bapat Marg
Elphinstone Road (West)
Mumbai - 400 013
Maharashtra, India

Tel: +91 22 6185 6000
Fax: +91 22 6185 4101

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF BAYER CROPSCIENCE LIMITED

1. We have reviewed the accompanying Statement of Unaudited Financial Results of BAYER CROPSCIENCE LIMITED ("the Company"), for the quarter and six months ended September 30, 2026 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").

2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **DELOITTE HASKINS & SELLS LLP**
Chartered Accountants
(Firm's Registration No. 117366W/W-100018)

MOHAMMED SAIFUDDIN BENGALI

Digitally signed by MOHAMMED SAIFUDDIN BENGALI
Date: 2026.11.03 17:55:50 +05'30'

Mohammed Bengali
Partner
Membership No. 105828
(UDIN: 26105828WYBMOE6304)

Mumbai
November 03, 2026

BAYER CROPSCIENCE LIMITED

(Registered Office: Bayer House, Central Avenue, Hiranandani Estate, Thane - 400 607, CIN L24210MH1958PLC011173)

PART I **₹ in Millions**

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED SEPTEMBER 30, 2026

PARTICULARS	Quarter Ended			Six Months Ended		Year Ended
	30.09.2026	30.06.2026	30.09.2025	30.09.2026	30.09.2025	31.03.2026
	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	AUDITED
Revenue from Operations	12,507	18,350	15,534	30,857	34,680	56,750
Other Income (Note 2)	134	889	138	1,023	325	950
Total Income	**12,641**	**19,239**	**15,672**	**31,880**	**35,005**	**57,700**
Expenses						
Cost of Materials Consumed	7,179	10,427	7,159	17,606	17,554	31,525
Purchases of Stock-in-Trade	384	683	1,021	1,067	1,651	2,200
Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	(428)	(743)	2,036	(1,171)	2,716	50
Employee Benefits Expense	1,055	1,128	1,125	2,183	2,168	4,381
Finance Costs	47	43	44	90	91	198
Depreciation and Amortisation Expense	150	501	144	651	416	940
Other Expenses	2,140	3,179	2,140	5,319	5,054	9,857
Total Expenses	**10,527**	**15,218**	**13,669**	**25,745**	**29,650**	**49,151**
Profit Before Tax	**2,114**	**4,021**	**2,003**	**6,135**	**5,355**	**8,549**
Tax Expense/ (Credit)						
- Current Tax	479	814	469	1,293	1,049	1,643
- Deferred Tax	(27)	(9)	7	(36)	(8)	14
Total Tax Expense	452	805	476	1,257	1,041	1,657
Profit for the period/ year	**1,662**	**3,216**	**1,527**	**4,878**	**4,314**	**6,892**
Other Comprehensive Income						
Items that will not be reclassified to profit or loss:						
- Remeasurement gain/ (loss) of Defined Benefit Plan	13	(7)	(7)	6	(13)	(162)
- Tax on remeasurement of Defined Benefit Plan	(3)	2	1	(1)	3	41
Total Other Comprehensive Income/ (Loss)	**10**	**(5)**	**(6)**	**5**	**(10)**	**(121)**
Total Comprehensive Income for the period/ year	**1,672**	**3,211**	**1,521**	**4,883**	**4,304**	**6,771**
Paid up Equity Share Capital (Face Value ₹ 10/-)	449	449	449	449	449	449
Reserves (excluding Revaluation Reserve as per Balance Sheet)						29,208
Earnings per share (basic and diluted) (^ not annualised) (in ₹)	36.98^	71.56^	33.98^	108.54^	95.99^	153.35

NOTES:

1. The Company has only one reportable business segment, i.e. "Agri Care". The Company's business is seasonal in nature and hence quarterly figures are not necessarily representative of the full year's performance.

2. Other Income includes:

₹ in Millions

PARTICULARS	Quarter Ended			Six Months Ended		Year Ended
	30.09.2026	30.06.2026	30.09.2025	30.09.2026	30.09.2025	31.03.2026
Gain on Divestment of Marketing Rights for Formulated Products	-	639	-	639	-	223

DELOITTE HASKINS & SELLS LLP CHARTERED ACCOUNTANTS

BAYER CROPSCIENCE LIMITED

(Registered Office: Bayer House, Central Avenue, Hiranandani Estate, Thane - 400 607, CIN L24210MH1958PLC011173)

NOTES (Contd):

3. Balance Sheet **₹ in Millions**

PARTICULARS	As at 30.09.2026 UNAUDITED	As at 31.03.2026 AUDITED
ASSETS		
Non-Current Assets		
Property, Plant and Equipment	3,887	4,015
Capital work-in-progress	55	49
Investment Property	239	241
Intangible Assets	382	328
Intangible Assets under development	1,134	1,225
Financial Assets		
- Other Financial Assets	49	44
Current Tax Asset (Net)	1,283	1,313
Deferred Tax Assets (Net)	159	124
Other Non-Current Assets	515	472
Total Non-Current Assets	**7,703**	**7,811**
Current Assets		
Inventories	20,649	21,355
Financial Assets		
- Investments	639	574
- Trade Receivables	18,198	11,155
- Cash and Cash Equivalents	4,709	14,146
- Bank Balances other than Cash and Cash Equivalents	75	72
- Other Financial Assets	558	122
Other Current Assets	2,841	1,759
Total Current Assets	**47,669**	**49,183**
TOTAL ASSETS	**55,372**	**56,994**
EQUITY AND LIABILITIES		
Equity		
Equity Share Capital	449	449
Other Equity	31,394	29,208
Total Equity	**31,843**	**29,657**
Liabilities		
Non-Current Liabilities		
Financial Liabilities		
- Lease Liabilities	362	388
Provisions	1,041	1,274
Total Non-Current Liabilities	**1,403**	**1,662**
Current Liabilities		
Financial Liabilities		
- Lease Liabilities	342	430
- Trade Payables		
Total outstanding dues of micro enterprises and small enterprises	248	279
Total outstanding dues of creditors other than micro enterprises and small enterprises	6,798	12,100
- Other Financial Liabilities	544	1,332
Other Current Liabilities	12,748	10,470
Provisions	899	1,019
Current Tax Liabilities (Net)	547	45
Total Current Liabilities	**22,126**	**25,675**
Total Liabilities	**23,529**	**27,337**
TOTAL EQUITY AND LIABILITIES	**55,372**	**56,994**

DELOITTE HASKINS & SELLS LLP CHARTERED ACCOUNTANTS

BAYER CROPSCIENCE LIMITED

(Registered Office: Bayer House, Central Avenue, Hiranandani Estate, Thane - 400 607, CIN L24210MH1958PLC011173)

NOTES (Contd):

4. Statement of Unaudited Cash Flow for Six Months Ended September 30, 2026

₹ in Millions

PARTICULARS	01.04.2026 to 30.09.2026 UNAUDITED	01.04.2025 to 30.09.2025 UNAUDITED
A. Cash Flow from Operating Activities:		
Profit Before Tax	6,135	5,355
Adjustments for:		
Interest Income from Financial Assets at Amortised Cost	(157)	(152)
Rent Income	(68)	(66)
Gain on Divestment of Marketing Rights for Formulated Products	(639)	-
Fair Value Loss/ (Gain) on Investments measured at Fair Value Through Profit or Loss (FVTPL) (Net)	25	(1)
Profit on Sale of Investments measured at Fair Value Through Profit or Loss (FVTPL) (Net)	(114)	(57)
Inventory Write Off/ Write Down	424	52
Finance Costs	90	91
Depreciation and Amortisation Expense	651	416
Loss on Disposal of Property, Plant and Equipment (Net)	-*	2
Loss on Intangible Assets Written Off	24	-
Bad Debts	5	11
Utilisation of Provision for Expected Credit Loss on Trade Receivable	(2)	(11)
Provision for Expected Credit Loss on Trade Receivables (Net)	177	272
Deposits Written Off	2	-
Provision for Doubtful Advances	5	6
Unrealised Foreign Exchange Fluctuations Loss/ (Gain)	4	(6)
	427	**557**
Operating profit before Working Capital changes	**6,562**	**5,912**
Adjustments for changes in Working Capital:		
(Increase)/ Decrease in Trade Receivables	(7,228)	(8,407)
(Increase)/ Decrease in Non-Current Financial Assets	(7)	-
(Increase)/ Decrease in Current Financial Assets	(497)	(47)
(Increase)/ Decrease in Other Non-Current Assets	(44)	(32)
(Increase)/ Decrease in Other Current Assets	(1,087)	(360)
(Increase)/ Decrease in Inventories	282	6,959
Increase/ (Decrease) in Trade Payables	(5,332)	(5,554)
Increase/ (Decrease) in Other Current Financial Liabilities	20	31
Increase/ (Decrease) in Non-Current Provisions	(244)	(177)
Increase/ (Decrease) in Current Provisions	(137)	(139)
Increase/ (Decrease) in Current Liabilities	2,157	2,121
Net changes in Working Capital	**(12,117)**	**(5,605)**
Cash (used in)/ generated from Operations	**(5,555)**	**307**
Taxes Paid	(761)	(656)
Net cash (used in) Operating Activities (A)	**(6,316)**	**(349)**
B. Cash Flow from Investing Activities:		
Purchase of Property, Plant and Equipment and Capital work-in-progress	(157)	(117)
Purchase of Intangible Assets and Intangible Assets under development	(65)	(216)
Proceeds from/ (Purchase of) Sale of Investments (Net)	19	(2)
Interest Received	191	167
Rent Received	95	78
Net cash generated from/ (used in) from Investing Activities (B)	**83**	**(90)**
C. Cash flows from Financing Activities		
Repayment of Principal Portion of Lease Liabilities	(445)	(216)
Interest Paid (including Interest Paid on Lease Liabilities)	(67)	(57)
Dividend Paid	(2,694)	(1,572)
Bank Balance in Unpaid Dividend Accounts	(3)	4
Net cash (used in) Financing Activities (C)	**(3,209)**	**(1,841)**
D. Net decrease in Cash and Cash Equivalents (A+B+C)	(9,442)	(2,280)
E. Cash and Cash Equivalents at the beginning of the year	14,146	8,855
Cash and Cash Equivalents at the end of the period	**4,704**	**6,575**
Reconciliation of Cash and Cash Equivalents with the Balance Sheet:		
Cash and Cash Equivalents as per Balance Sheet	4,709	6,579
Adjustment for Fair Value gain on liquid investments measured through profit or loss	(5)	(4)
F. Cash and Cash Equivalents at the end of the period (D+E)	**4,704**	**6,575**

*represents amount below the rounding off norm adopted by the Company.

DELOITTE HASKINS & SELLS LLP CHARTERED ACCOUNTANTS

BAYER CROPSCIENCE LIMITED

(Registered Office: Bayer House, Central Avenue, Hiranandani Estate, Thane - 400 607, CIN L24210MH1958PLC011173)

NOTES (Contd):

PARTICULARS	As at 30.09.2026	As at 30.09.2025
Cash and cash equivalents comprise:		
Balances with Banks	2,523	4,789
Short-term Highly Liquid Investments	2,186	1,790
	4,709	**6,579**

4a. The above Statement of Cash Flow has been prepared under the "Indirect Method" set out in Ind AS 7 - Statement of Cash Flows.
4b. Short-term highly liquid investments comprise of Investment in Mutual Funds which are highly liquid and have an insignificant risk of change in value.

5. The Company does not have any subsidiary, joint venture, or associate company and consequently, the Company is not required to prepare consolidated financial results under Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2025.

6. The Board of Directors at its meeting held on November 3, 2026 declared an interim dividend of ₹ 90 per equity share for the financial year ending March 31, 2027 amounting to ₹ 4,045 Million for 44,942,092 equity shares of ₹ 10/- each. The record date for the purpose of determining the entitlement for payment of interim dividend is fixed as November 12, 2026.

7. The above results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors of the Company at its meeting held on November 3, 2026. The above results have been subjected to limited review by the Statutory Auditors of the Company.

By Order of the Board

VINIT RAJESH JINDAL
Digitally signed by VINIT RAJESH JINDAL
Date: 2026.11.03 17:41:27 +05'30'

Vinit Jindal
Executive Director and Chief Financial Officer
DIN: 10849465

DELOITTE HASKINS & SELLS LLP CHARTERED ACCOUNTANTS

Place: Thane
Date: November 3, 2026